Clinical Trials
58 trialsBuMelMCRN001
University Health Network, Toronto
CARTITUDE-2
Janssen Research & Development, LLC
MonumenTAL-1
Janssen Research & Development, LLC
IMPACT
University of Utah
MMRC Horizon One: RRMM (MMRC-099)
Multiple Myeloma Research Consortium
Talisman
Janssen Research & Development, LLC
MonumenTAL-8
Janssen Research & Development, LLC
aMMbition
Janssen Research & Development, LLC
CARTITUDE-10
Janssen Research & Development, LLC
TRIlogy-3
Janssen Research & Development, LLC
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes
PETHEMA Foundation
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Duke University
FASTER
SCRI Development Innovations, LLC
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
KRDI in Transplant-Eligible MM
Massachusetts General Hospital
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities
Institute of Hematology & Blood Diseases Hospital, China
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
MASTER-2
University of Alabama at Birmingham
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)
National Cancer Institute (NCI)
TAPUR
American Society of Clinical Oncology
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
City of Hope Medical Center
18F-Fluciclovine PET/CT in Multiple Myeloma
National Institutes of Health Clinical Center (CC)
BELAMI
Centre Hospitalier Universitaire de Saint Etienne
DREAMM-16
GlaxoSmithKline
QUINTESSENTIAL
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
National Cancer Institute (NCI)
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
National Cancer Institute (NCI)
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
National Cancer Institute (NCI)
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
National Cancer Institute (NCI)
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
National Cancer Institute (NCI)
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
National Cancer Institute (NCI)
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)
National Cancer Institute (NCI)
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
National Cancer Institute (NCI)
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
National Cancer Institute (NCI)
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
University of Arkansas
POM MM 014
Celgene
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
M.D. Anderson Cancer Center
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
UNC Lineberger Comprehensive Cancer Center
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Pfizer
Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Medical College of Wisconsin
Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
Memorial Sloan Kettering Cancer Center